started · updated
AxoGen raises 2026 revenue guidance following strategic acquisition
AxoGen has increased its full-year 2026 revenue guidance to a minimum of $290 million, according to its third-quarter earnings report. The company cited broader adoption of its nerve repair portfolio across various surgical specialties and expanded health plan coverage as primary growth drivers.
Key developments include the acquisition of BioCircuit, which introduced NerveTape, a sutureless device designed for faster connection of severed nerves. This acquisition allows AxoGen to enter the direct nerve repair market, which accounts for approximately 40% to 50% of transected nerve procedures.
Additionally, the company reported that commercial payer coverage for its Avance Nerve Graft product has reached approximately 96% of covered lives in the United States. AxoGen is also preparing for a 2027 market launch focused on prostate nerve reconstruction following clinical data indicating meaningful function restoration in 80% of patients.
Entities
Aetna · AxoGen · BioCircuit · Elevance · Michael Dale